Glabridin vs Alpha-Arbutin vs Kojic Acid Dipalmitate: Buyer Guide

Quick Answer

There is no evidence-based universal winner among Glabridin, Alpha-Arbutin and Kojic Acid Dipalmitate (KAD). They are different chemical materials, they behave differently in formulation, and their evidence and regulatory questions are not interchangeable.

For a buyer, the most useful comparison order is: exact identity -> formulation phase and solubility -> evidence relevant to the intended system -> COA and analytical method -> destination-market regulatory scope -> effective sourcing cost. Price per kilogram and headline purity should come later.

Alpha-Arbutin is comparatively straightforward to evaluate for water-phase systems because it is a defined water-soluble glycoside. Free Glabridin has poor water solubility, so the commercial format matters greatly. KAD is an esterified, lipophilic material and should be evaluated as a separate ingredient rather than as a 'more stable Kojic Acid grade.'

The right question is therefore not 'Which active is strongest?' It is 'Which material can be verified, formulated, regulated and sourced for this exact product?'

What Is the Difference Between Glabridin, Alpha-Arbutin and Kojic Acid Dipalmitate?

The first difference is chemical identity. These materials should never be treated as three grades of one generic brightening ingredient.

Glabridin is a defined licorice-derived isoflavan identified by PubChem as CAS 59870-68-7.[1] Alpha-Arbutin is a defined glycoside, CAS 84380-01-8.[2] Kojic Acid Dipalmitate is an esterified Kojic Acid derivative commonly supplied under CAS 79725-98-7, but commercial naming and structure records are not always presented consistently across public sources.[3] That makes supplier-document consistency especially important for KAD.

For procurement, a percentage such as 98% only describes the assay or purity statement for that exact material under a stated method. It does not create a common potency scale across three different molecules.

Buyer action: before comparing price, match product name, CAS number, supplier product code, stated assay, analytical method and batch documentation. If those fields conflict, stop the commercial comparison until the identity is resolved.

Which One Fits Water-Phase, Oil-Phase or Emulsion Systems?

Formulation fit is often more decisive than a marketing claim about potency.

Alpha-Arbutin is water-soluble in established technical references and supplier analytical data, which makes it a natural candidate for evaluation in aqueous phases. That does not remove the need to control processing temperature, pH and long-term stability, but it simplifies the first formulation decision.

Free Glabridin has poor water solubility. Peer-reviewed work has therefore explored cyclodextrin complexes, nanoemulsions, mesoporous carriers and other delivery approaches to improve aqueous compatibility.[6] Commercial 'water-soluble Glabridin' should be treated as a delivery system or modified format until the supplier documents the carrier, loading and assay basis.

Kojic Acid Dipalmitate is lipophilic and has been described in peer-reviewed literature as almost insoluble in water. It may therefore be evaluated for oil-phase or emulsion routes, but the exact solvent system, processing temperature and recrystallization risk are grade-specific questions for the supplier and the formulator.

Do not reduce the decision to 'serum = Alpha-Arbutin' and 'cream = KAD.' Modern formulas may contain co-solvents, emulsifiers, encapsulation systems or separate phase additions. Use the physical system as a screening criterion, not as a universal recipe.

What Does the Evidence Actually Support?

The evidence packages are not symmetrical, so a simple winner table would create false precision.

Glabridin has independent evidence for tyrosinase inhibition and older in-vivo topical work, including the classic 1998 study that reported inhibition of melanogenesis and UVB-induced pigmentation in experimental models.[4] It also has a substantial biochemical literature. However, those data do not automatically predict the performance of every commercial Glabridin grade or finished formula.

Alpha-Arbutin has a well-defined regulatory safety dossier in the EU and published analytical and formulation literature. Clinical evidence also exists for formulas containing Alpha-Arbutin, including combination studies, but a combination formula cannot prove the isolated contribution of Alpha-Arbutin or establish superiority over Glabridin or KAD.[11]

KAD has formulation, analytical and delivery-system research, including direct work on its stability under specific oxidative stress conditions. Modern KAD studies often evaluate a particular gel, emulsion, ethosome or nanocapsule system rather than a generic bulk powder. Those results should not be transferred to every supplier grade.

Buyer action: classify evidence by what it actually tested - raw material, enzyme assay, cell model, animal model, finished formulation or human use. A stronger result in one model is not a universal cross-material ranking.

Can You Compare Their Potency by IC50, Purity or Use Level?

Not as a single universal score.

Current commercial comparison pages often use in-vitro tyrosinase IC50 values to argue that one ingredient is many times 'stronger' than another. IC50 can be useful inside one defined assay, but it is assay-dependent and does not capture solubility, delivery, formulation stability, skin exposure, analytical purity or finished-product performance.

The same problem applies to purity. A 98% Alpha-Arbutin result, a 98% KAD result and a 98% Glabridin result are three separate specification statements. They may use different analytical methods and they do not represent equivalent active strength in a finished cosmetic.

Use level is also not a universal potency converter. Regulatory limits, supplier recommendations, delivery systems and formulation constraints can all change the practical concentration range. Do not turn molecular weight, IC50 or nominal use level into a made-up 'equivalent strength' number for supplier ranking.

Buyer action: compare potency claims only when the assay design, material identity, test conditions and endpoint are sufficiently comparable. For sourcing, prioritize whether the exact commercial material can meet the product requirement.

Which One Is More Stable?

There is no condition-free answer.

Glabridin's practical challenge is often its physical and formulation behavior, including poor water solubility. Delivery systems can materially change that behavior, so stability claims should be tied to the exact grade and matrix.

Alpha-Arbutin requires control of identity, purity and Hydroquinone-related quality risk. The EU SCCS concluded that Hydroquinone in Alpha-Arbutin-containing cosmetic formulations should remain as low as possible and not exceed unavoidable trace levels. That is a regulatory and quality-control issue, not a reason to convert one supplier's internal ppm specification into a universal legal number.

KAD is commonly marketed as a more stable Kojic Acid derivative, but this cannot be stated as universal fact. In a 2022 peer-reviewed comparison under liquid oxidative stress induced by hydrogen peroxide, KAD degraded more rapidly than Kojic Acid under the tested conditions.[10] The practical lesson is that stability must name the stress condition, formulation system and analytical endpoint.

Buyer action: ask for the exact stability evidence relevant to your planned pH, phase, processing temperature, packaging, light exposure, oxygen exposure and storage period.

How Do Their Regulatory Questions Differ?

Regulatory review must follow exact chemical identity. Similar use in a brightening formula does not create one shared regulatory rule.

In the European Union, Commission Regulation (EU) 2024/996 restricts Alpha-Arbutin to a maximum concentration of 2% in face creams and 0.5% in body lotions. It also requires Hydroquinone in cosmetic products containing Alpha-Arbutin or Arbutin to remain no higher than unavoidable trace levels.[7][8]

Kojic Acid Dipalmitate must not be treated as if it were covered by the Kojic Acid SCCS opinion. The SCCS explicitly stated that Kojic Acid derivatives, including Kojic Acid Dipalmitate, were not included because no data had been submitted for those derivatives in that opinion.[9]

The correct conclusion is not that KAD is automatically unrestricted. It means the Kojic Acid conclusion cannot simply be transferred to KAD. The same identity-specific discipline applies to Glabridin: verify the current rules, product category and destination market for the exact commercial material rather than importing another ingredient's limit.

Buyer action: for every target market, document the exact INCI/chemical identity, product category and current legal source before commercialization.

What Should You Compare on the COA?

Use separate COA logic for each ingredient, then compare document quality rather than forcing identical test panels.

For Glabridin, verify the exact product identity, stated grade or assay, batch number, analytical method or method reference, actual batch result and any carrier or delivery-system information that affects the commercial format. A statement such as 'HPLC tested' is not enough by itself to prove method equivalence across suppliers.

For Alpha-Arbutin, verify Alpha-Arbutin identity rather than generic 'Arbutin,' batch traceability, assay specification versus actual result, analytical method, and Hydroquinone-related testing where it is part of the quality specification. Remember that a supplier specification limit is not automatically a regulatory limit.

For KAD, verify exact naming, CAS/product code consistency, batch identity, assay method, structural identity information where available, and formulation-relevant properties such as solubility or incorporation guidance. Public supplier records are not always perfectly consistent, so cross-document consistency matters.

A sample or representative COA shows the supplier's reporting format. It does not prove the result of the lot you will receive. For commercial qualification, request batch-specific documentation when available.

For field-by-field interpretation, use the Glabridin COA guide and the Alpha-Arbutin COA guide.

How Should Buyers Compare Sourcing Cost?

Do not compare these three materials by price per kilogram alone, and do not convert them into a universal cost-per-'brightening power' number.

Within the same identity, normalize quote unit, assay, MOQ, package size, freight basis, documentation, testing and lead time. For Glabridin, cost per gram of stated active can be useful when comparing different assays of the same material family. The Glabridin bulk price guide explains that calculation.

Across different identities, move one level higher and compare effective project cost. That may include formulation solvents or carriers, processing changes, stability work, packaging, incoming QC, regulatory work, sample and pilot cost, rejected-batch risk and supplier qualification time.

A higher raw-material price can still produce a lower project cost if it reduces another material or process burden. The reverse can also be true. Without real formulation and quote data, do not invent a universal cost winner.

Marketplace display prices remain discovery signals, not verified transaction prices. Final commercial comparisons should use like-for-like quotations with quantity, unit, Incoterm and validity date stated.

Current Alibaba Sourcing Links

The following links are current sourcing examples for the three ingredient identities discussed above. They are not a supplier ranking or an endorsement. Before purchase, recheck the exact product identity, current specification, batch documentation, MOQ, availability and quotation terms.

For procurement comparison, treat these as starting points for supplier due diligence. Use the RFQ structure below so each offer is evaluated on the same identity, evidence and commercial fields.

Buyer Decision Matrix: Which Material Should Enter Your Shortlist First?

Use this as a screening sequence, not as an automatic winner selector.

If your project is primarily aqueous and you want the simplest first-pass incorporation route, evaluate Alpha-Arbutin first. Then verify its exact assay, Hydroquinone-related quality controls, processing window and destination-market rules.

If your project specifically wants Glabridin as a defined licorice-derived active, evaluate whether the commercial grade is raw high-assay material or a formulated/solubilized delivery system. The formulation route and carrier can be as important as the assay percentage.

If your project requires a lipophilic active for an oil phase or emulsion route, KAD may be a rational candidate to evaluate. Do not select it merely because a supplier calls it 'more stable'; request condition-specific stability and incorporation data.

If two or three materials remain technically viable, prototype them under the same acceptance criteria. Compare finished-formula stability, analytical control, sensory impact, manufacturing complexity, regulatory fit and effective sourcing cost.

If the only reason for choosing a material is a headline such as '30x stronger,' 'more stable,' 'premium,' or 'natural,' stop and ask what evidence connects that claim to the exact commercial grade and your actual formulation.

Can You Use More Than One of These Actives in the Same Formula?

Possibly, but combination should be treated as a formulation project rather than assumed synergy.

There are published finished-formula studies involving combinations of brightening actives, and current market products often combine multiple mechanisms. However, a combination study does not prove that every pair is synergistic, nor does it prove that a supplier's bulk materials will remain physically and chemically compatible in your system.

Before combining, check phase compatibility, pH, processing temperature, solubility, total solids, preservative system, packaging, analytical method and stability plan. If KAD and Alpha-Arbutin occupy different phases, for example, the emulsion design and cooling sequence may matter more than a theoretical mechanism diagram.

Buyer action: qualify each active separately first, then evaluate the combination in the actual finished formula. Do not use a consumer stacking article as a substitute for formulation validation.

What Should Your Supplier RFQ Include?

Send the same core RFQ structure to every serious supplier so the responses can be compared.

Request: exact ingredient name and INCI where applicable; CAS number; supplier product code/grade; current specification; batch-specific or representative COA; assay and analytical method; TDS and SDS; carrier or delivery-system composition where relevant; sample quantity; pilot and commercial MOQ; package size; target-quantity price; price breaks; freight/Incoterm basis; lead time; quote validity; storage and shelf-life documentation; and destination-market compliance documents where applicable.

For Glabridin, add questions about assay basis, matrix/carrier and whether 'water-soluble' or other delivery claims refer to a formulated system. For Alpha-Arbutin, add Alpha-versus-Beta identity control and Hydroquinone-related quality data where applicable. For KAD, add solubility/incorporation guidance, exact identity controls and evidence behind any improved-stability claim.

The goal is not to collect the largest dossier. It is to remove the uncertainties that change the buying decision.

Which One Should You Choose?

Choose the material that best survives the full decision chain: identity -> formulation fit -> evidence -> batch verification -> regulatory fit -> economics.

Alpha-Arbutin may be the easiest first candidate in many water-phase systems, but it carries its own identity, Hydroquinone-trace and regulatory questions. Glabridin can support a differentiated licorice-derived positioning, but the commercial format and solubility system must be understood. KAD can fit lipophilic or emulsion routes, but its stability should be verified under the conditions that actually matter to the formula.

There is no defensible universal ranking that says one of these three is always the best brightening active. The procurement objective is to choose a qualified material for a defined formula and market, then compare suppliers inside that identity on evidence and effective cost.

References

[1] PubChem - Glabridin, CID 124052; CAS 59870-68-7. [2] PubChem - Alpha-Arbutin, CID 158637; CAS 84380-01-8. [3] PubChem - Kojic Acid Dipalmitate / Kojic dipalmitate records associated with CAS 79725-98-7. Public records should be reconciled with supplier identity documents before procurement. [4] Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Research. 1998;11(6):355-361. PMID: 9870547. [5] Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160-184. PMID: 23850540. [6] Wei Y, et al. Characterization of glabridin/hydroxypropyl-beta-cyclodextrin inclusion complex with robust solubility and enhanced bioactivity. Carbohydrate Polymers. 2017;159:152-160. PMID: 28038744. [7] Scientific Committee on Consumer Safety (SCCS). Opinion on the safety of alpha- and beta-arbutin in cosmetic products. SCCS/1642/22. Final opinion, 31 January 2023. [8] Commission Regulation (EU) 2024/996 of 3 April 2024 amending Regulation (EC) No 1223/2009, including Alpha-Arbutin and Kojic Acid entries. [9] Scientific Committee on Consumer Safety (SCCS). Scientific Opinion on Kojic Acid. SCCS/1637/21, final version and corrigendum, 2022. The opinion explicitly states that Kojic Acid derivatives including Kojic Acid Dipalmitate were not included because no derivative data were submitted. [10] Tazesh S, et al. Comparative Stability of Two Anti-hyperpigmentation Agents: Kojic Acid as a Natural Metabolite and Its Di-Palmitate Ester, Under Oxidative Stress. Advanced Pharmaceutical Bulletin. 2022;12(2):329-335. PMID: 35620332. [11] Tantanasrigul P, Sripha A, Chongmelaxme B. The Efficacy of Topical Cosmetic Containing Alpha-Arbutin 5% and Kojic Acid 2% Compared With Triple Combination Cream for the Treatment of Melasma. Journal of Cosmetic Dermatology. 2025;24:e16562. This is a combination-formula study of Alpha-Arbutin plus Kojic Acid, not KAD and not a raw-material head-to-head comparison.

Glabridin vs Alpha-Arbutin vs Kojic Acid Dipalmitate: A Buyer's Comparison